New Hyperhidrosis Treatments in 2026: Sofpironium Gel and Brella Patch Explained

The landscape of hyperhidrosis treatment is evolving rapidly, with several innovative options now available to the millions of Americans who experience excessive sweating. If you've found that over-the-counter antiperspirants aren't providing adequate relief, understanding these newer treatment modalities can help you have more informed conversations with your dermatologist about what might work best for your specific situation.

The Growing Need for Effective Hyperhidrosis Solutions

Primary axillary hyperhidrosis affects approximately 4.8% of the U.S. population, characterized by excessive underarm sweating that goes far beyond what's needed for normal thermoregulation. This condition significantly impacts quality of life, often necessitating frequent clothing changes and causing considerable psychosocial distress. While traditional treatment options like prescription antiperspirants, oral anticholinergics, and botulinum toxin injections have helped many patients, a substantial number remain dissatisfied due to invasiveness, side effects, or limited efficacy.

The good news? Pharmaceutical innovation in this space is accelerating. Two recent FDA-approved treatments—sofpironium gel and the Brella SweatControl Patch—represent meaningful advances in non-invasive hyperhidrosis management.

Sofpironium Gel: A New Topical Approach

Sofpironium bromide topical gel (marketed as Sofdra) received FDA approval in 2024 for the treatment of primary axillary hyperhidrosis in adults and pediatric patients aged nine years and older. This represents a significant addition to the topical treatment arsenal.

How Sofpironium Works

Sofpironium is designed to maximize local effectiveness while minimizing systemic side effects. The active ingredient blocks specific receptors in sweat glands that are responsible for stimulating sweat production. When you apply sofpironium gel to your underarms, it blocks the signal that tells your sweat glands to produce moisture.

What distinguishes sofpironium from other anticholinergic treatments is its rapid metabolism into inactive compounds once absorbed. This characteristic substantially reduces the likelihood of systemic anticholinergic side effects—such as dry mouth, blurred vision, and constipation—that have historically limited patient adherence to oral anticholinergic medications.

Clinical Evidence

Two large clinical studies involving approximately 700 participants with primary axillary hyperhidrosis demonstrated compelling results. More than 60% of patients treated with sofpironium gel experienced a 50% or greater reduction in sweat production. Perhaps more importantly, 85% of patients reported clinically meaningful improvement in their condition.

Patients in these studies reported symptom relief as early as one week after initiating treatment, with continued benefits throughout the six-week trial period. The gel requires daily application to maintain its effect—discontinuing treatment results in return of normal sweat production.

Side Effect Profile

The side effect profile of sofpironium appears more favorable than that of topical glycopyrronium (Qbrexza), another FDA-approved topical anticholinergic. Treatment-emergent adverse events were primarily mild to moderate. Dry mouth occurred in approximately 14.2% of patients, which compares favorably to rates reported with other anticholinergic treatments. Application-site reactions, blurred vision, and mydriasis (pupil dilation) were also reported but remained relatively uncommon.

The Brella SweatControl Patch: Targeted Heat Therapy

The Brella patch represents an entirely different approach to hyperhidrosis treatment—one that doesn't rely on blocking chemical signals but instead uses targeted thermal energy to reduce sweat gland activity.

The TAT Technology Explained

Brella uses Candesant Biomedical's patented Targeted Alkali Thermolysis (TAT) technology. The patch is a single-use disposable device containing sodium that, when applied to the underarm, reacts with the water in your sweat to generate localized thermal energy. This heat is precisely targeted at sweat glands at the microscopic level, reducing their capacity to produce sweat without damaging surrounding tissue.

The treatment takes approximately three minutes per underarm and is performed in a dermatologist's office. It's completely non-invasive, needle-free, and doesn't involve any aluminum-based compounds. Results typically last three to four months, making it a periodic rather than daily treatment option.

Clinical Validation

FDA clearance of Brella was based on the SAHARA study, a randomized, double-blind, sham-controlled trial involving 110 adults with primary axillary hyperhidrosis. All participants had baseline Hyperhidrosis Disease Severity Scale (HDSS) scores of 3 or 4, indicating that sweating frequently or always interfered with their daily activities.

The study achieved both its primary and secondary endpoints, demonstrating meaningful sweat reduction and improved quality of life. Importantly, the treatment was well-tolerated with no serious adverse events reported. Responders were followed for up to 24 weeks post-treatment, confirming the durability of results.

Comparing Your Treatment Options

Understanding how these new treatments fit into the broader hyperhidrosis treatment landscape can help you determine which approach might be most appropriate for your needs.

First-Line Treatments

For most people experiencing excessive underarm sweating, the journey typically begins with over-the-counter clinical-strength antiperspirants. Products like Carpe Underarm Antiperspirant contain aluminum sesquichlorohydrate, which forms temporary plugs in sweat ducts to reduce perspiration. Carpe's lotion-based formulation features Triple Action Protection — controlling sweat, killing odor-causing bacteria, and nourishing skin — with clinically tested 100-hour sweat and odor control. It's an excellent starting point for daily sweat management before considering prescription options.

For those needing on-the-go touch-ups, Underarm Wipes offer convenient sweat control throughout the day. And for individuals who prefer a stick format or need higher-concentration active ingredients, the Underarm AM Stick provides 20% aluminum zirconium tetrachlorohydrex gly.

When to Consider Prescription Treatments

If over-the-counter options don't provide sufficient relief, it may be time to discuss prescription treatments with your dermatologist. The decision between sofpironium gel, Brella, and other options like Botox for axillary hyperhidrosis depends on several factors:

Sofpironium gel may be ideal if you:

• Prefer a daily at-home treatment routine
• Want to avoid in-office procedures
• Have concerns about systemic side effects from oral medications
• Are looking for a non-invasive option

Brella may be better suited if you:

• Prefer periodic rather than daily treatment
• Want to avoid aluminum-based products entirely
• Don't mind in-office visits every 3-4 months
• Want needle-free treatment

Botulinum toxin injections remain an option for those who:

• Haven't responded to topical treatments
• Are comfortable with injections
• Can commit to treatments every 4-6 months

To understand how hyperhidrosis treatments have evolved, it's worth noting that we now have more options than ever before—a trend that continues as pharmaceutical research in this space expands.

The Future of Hyperhidrosis Treatment

Research continues to advance in hyperhidrosis management. Ongoing studies are exploring combination therapies, new delivery mechanisms, and treatments targeting different aspects of sweat gland function. The International Hyperhidrosis Society maintains updated information on treatments in development for those interested in following the latest clinical trials.

One particularly promising area involves oral combination therapies designed to minimize side effects. Researchers are investigating formulations that pair anticholinergic medications with agents that counteract common side effects like dry mouth, potentially making systemic treatment more tolerable for patients with multifocal hyperhidrosis affecting areas beyond the underarms.

Taking the Next Step

If you're exploring treatment options for excessive sweating, consider starting with clinically tested over-the-counter solutions. For many people, products designed for daily sweat management provide meaningful relief without the need for prescription treatments.

However, if you've been understanding primary focal hyperhidrosis and find that your symptoms significantly impact your daily life, don't hesitate to discuss newer options like sofpironium gel or Brella with a board-certified dermatologist. The expanding treatment landscape means there's likely an approach that can work for your specific situation.

In summary, 2026 represents an exciting time for hyperhidrosis treatment. With FDA-approved options like sofpironium gel offering daily topical management and Brella providing periodic in-office treatment, patients now have more pathways to meaningful sweat control than ever before. Combined with effective over-the-counter antiperspirants, the comprehensive sweat-care toolkit continues to grow.

References

Pariser D, Glaser DA, Del Rosso J, et al. Sofpironium topical gel for axillary hyperhidrosis: pooled results from two phase 3 studies. Journal of the American Academy of Dermatology. 2025;93(1):82-88.

Del Rosso J, Hebert A, Cartwright M. Sofpironium shows early meaningful improvement in primary axillary hyperhidrosis symptoms. J of Skin. 2025.